Brief: Matinas Biopharma Announces Initiation Of Enhance-It Study Of Mat9001 Against Vascepa
05/03/2020 12:21
March 5 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA ANNOUNCES INITIATION OF ENHANCE-IT STUDY
OF
MAT9001 AGAINST VASCEPA®
* MATINAS BIOPHARMA HOLDINGS INC - TOPLINE DATA EXPECTED Q4
2020
Source text for Eikon: ID:nGNX3pQWxW
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing
Brief: Matinas Biopharma Holdings Inc Keith Kucinski Resigns As CFO Effective January 17, 2026
Brief: Matinas Biopharma Holdings Inc - CFO Keith Kucinski Resigns Effective January 17, 2026 - SEC Filing
Brief: Matinas Biopharma Holdings Eric Ende Resigns As Chairman Of Matinas Biopharma
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors